Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
CNMD's Q3 earnings beat estimates on the back of higher revenues and lower costs and expenses.
CONMED Corporation (NYSE:CNMD ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Curt Hartman – Chairman, President and Chief Executive Officer Pat Beyer – Chief Operating Officer Todd Garner – Executive Vice President and Chief Financial Officer Conference Call Participants Kristen Stewart – C.L. King Lily Delaney – JPMorgan Dino Weinstock – Wells Fargo Operator Good day and thank you for standing by.
The headline numbers for Conmed (CNMD) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Conmed (CNMD) came out with quarterly earnings of $1.05 per share, beating the Zacks Consensus Estimate of $0.99 per share. This compares to earnings of $0.90 per share a year ago.
Conmed (CNMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Conmed (CNMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
CNMD is poised for growth with strong product offerings and recurring revenues but faces headwinds from regulatory challenges, supply-chain constraints and cybersecurity risks.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock?